India, Aug. 10 -- Shares of Faeth Therapeutics, Inc. (FTH) are up over 18% today.
The company recently provided an update on its oncology pipeline and reported its second-quarter 2026 financial results, with investors focusing on progress in the PIKTOR program and upcoming clinical milestones.
Recent Business & Clinical Updates:
Faeth's Phase 2 PIK-201 trial evaluating PIKTOR in second-line advanced endometrial cancer remains on track for topline results by year-end 2026.
The company dosed the first patient in its Phase 1b/2 PIK-101 trial evaluating PIKTOR in HR+/HER2- advanced breast cancer. Initial safety and efficacy data are expected in 2027.
Faeth also presented PK/PD modeling and translational data at the 2026 STOP Cancer confere...